Organon shelves contraceptive with 'natural' estrogen

13 Feb 2024

Phase 3Clinical Trial Termination

Organon’s attempt to revive a once-rejected “natural” contraceptive is over, a spokesperson confirmed to Endpoints News. The Merck women’s health spinoff has terminated a Phase III trial for NOMAC-E2 early due to “business reasons,” the spokesperson said. The company said the decision was unrelated to the drug’s safety. NOMAC-E2 was developed by Theramex, a women’s health business that was once part of Merck KGaA and Teva. The candidate has been touted as a “natural” alternative to other contraceptives using synthetic estrogen, because it contains a version of the hormone that’s structurally identical to estrogen produced in the body.

For more details,please visit the original website

The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.

Organizations

Organon & Co.

Merck & Co., Inc.

Theramex HQ UK Ltd.

[+1]

Indications

Targets

Drugs

Nomegestrol acetate/EstradiolVitamin A Retinol AcetateEstrogen(MEDIR)

Hot reports

Global Drug R&D Express (Apr 2024)

PatSnap Synapse

Global Drug R&D Express (Mar 2024)

PatSnap Synapse

Global Drug R&D Express (Feb 2024)

PatSnap Synapse

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.